Northwest Health Prop Real Est Inv TrustNWH.UN.TOHOLDMay 15, 2023Stock price when the opinion was issued
As of Mar 10, 2026. Market Open.
Interesting mix of assets. Medical offices in Canada, hospitals and such in Europe, NZ, and Australia. Took on a lot of debt, paid a big dividend, and then it all didn't work out very well. Management got replaced, new management doing a good job.
Now much leaner. Curtailing footprint and driving synergies. Likes international footprint because of long-dated leases with inflation escalators. Canadian leases are more short-term. "OK" at this price, but not a screaming buy. Rumours of a takeover. You could buy for the dividend, but he'd wait for a pullback. Don't expect much price appreciation.
As did many companies, had to refinance its debt in 2022, going from 1-2% to 5%. That was a big headwind. Had to do a fire sale on some assets. Now stabilized. NAV is ~$7.50-8 per share. New CEO taking action to realize underlying value of the company.
A recent Top Pick, so he really likes it. Great entry point. Not a lot of economic sensitivity. Paying down debt, buying back stock and bonds. Yield is ~7%.
Hospital and medical offices around the globe, very strong assets, some with 10- or 20-year leases. Hit hard in 2022 with higher interest rates on too much debt. Replaced CEO. One of the cheapest REITs on the market.
Chairman owns about 10% of the stock, just through open-market purchases. He likes management that puts their own $$ in. Yield is 7.10%.
Lower beta, boring for this time of year. Two overlooked sectors in one -- healthcare and REITs. Steady eddy. Should probably hold its own between now and the fall, when he'll probably exit. Collect the dividend, might go up a couple of bucks, better than cash. Decent yield of 7.34%.
(Analysts’ price target is $5.57)It is caught up in the interest rate environment. Pays a 7 1/2% dividend and is in the defensive healthcare space. Has long term leases with rent escalators built in. Debt is down and cash flow up. The payment ratio is very sustainable. This will be the first earnings call for the new CEO.
Yes, in much better position today than previously. Management transition. Hard to see it going back to $10 levels anytime soon. Decent job allocating capital (ie. selling assets) to pay down debt. Enough to pay March debentures. Risk/reward not that compelling.
One of the most attractive REITs on the TSX right now. Coming out of poor fundamental operations where capital allocation was mismanaged. New CEO cut dividend, sold properties. Prepared either way if interest rates fall or rise. Payout ratio will fall closer to 80%. Stock may have fallen recently because that new CEO is retiring next year. Yield is 7.3%, one of the highest out there.
We would consider results OK. Cash flow per share of 16c did miss estimates of 17c, but revenue of $135M beat estimates of $122M. Payout ratio has risen but on an annual basis was 68% in 2022. Operating income increased, offset by higher rates. Occupancy is good at 97%, leases are long and many are indexed. The convertible issue, the institutional investor and the planned asset sales should add a lot more financial flexibility. The proof will be in the pudding but the comments we think make the point that management knows that leverage and recession concerns are hurting their valuation. We are not sure the corned has been turned, but are more optimistic than pessimistic, largely because of its already-low valuation.
Unlock Premium - Try 5i Free